MIDAMOR (amiloride hydrochloride) by Design Pharmaceuticals is clinical pharmacology amiloride hcl is a potassium-conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. Approved for hypertension. First approved in 1981.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
MIDAMOR (amiloride hydrochloride) is a potassium-conserving diuretic used to treat hypertension, typically as an adjunct to thiazide or loop diuretics. It works by inhibiting sodium reabsorption in the distal convoluted tubule and collecting duct, thereby reducing potassium and hydrogen secretion. The drug has weak natriuretic and diuretic activity compared to thiazide diuretics but preserves serum potassium levels.
Product approaching loss of exclusivity with minimal current market data; limited career growth opportunities for brand-focused roles.
CLINICAL PHARMACOLOGY Amiloride HCl is a potassium-conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. These effects have been partially additive to the effects of thiazide diuretics in some clinical studies.…
Worked on MIDAMOR at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions
Working on MIDAMOR offers limited career advancement as the product approaches loss of exclusivity with minimal linked job opportunities. This role is suited for professionals managing portfolio transition, generic rollout strategy, or cost-containment positioning rather than growth-focused career trajectories.